Medtronic PLC vs ZIM Integrated Shipping Services Ltd — how do they compare? Medtronic PLC trades at $90.93 (market cap $116.07B), while ZIM Integrated Shipping Services Ltd trades at $25.21 (market cap $2.96B). The key difference: Medtronic PLC is far larger — about 39.2× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| MDT | ZIM | |
|---|---|---|
Market Cap | $116.07B | $2.96B |
Sector | Health | Industrials |
52-Week High | $105.35 | $29.27 |
52-Week Low | $73.75 | $12.44 |
Enterprise Value | $134.82B | $6.81B |
Dividend Yield | 3.18% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
ZIM trades at $25.29, up 0.32% on the day, amid a bearish technical outlook and mixed earnings performance. The stock shows weak profitability with a net margin of 1.56% and declining revenue projections for 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and upcoming Q2 2026 earnings, with analyst sentiment evenly split between hold and sell recommendations.
The outlook for ZIM is cautious, with risks from merger uncertainty and operational pressures outweighing its low valuation multiples. Investment opportunity hinges on successful execution and merger approval, but current fundamentals and bearish technicals suggest limited near-term upside amid high volatility.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →